Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings

Dow Jones

昨天

0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2667656833"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667656833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667656833?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667656833","market":"fut","top_or_hot":-1,"title":"Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0740 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-14 15:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0740 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2667656833","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667656833","pubTimestamp":1789371600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1583":"高瓴概念","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK1589":"北水核心资产","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC"},"translate_title":"信达扩大现金持有量，投资公允价值可能会提高盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":0.6,"01801":1.95},"content_text":"0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}